SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the crypto market experiences volatility, sparking debates about potential bottom levels and the impact of large holders like MicroStrategy. Community discussions range from calling it a "pedo ponzi coin" to anticipating a surge to $200K, highlighting the highly polarized sentiment around its future. Investors are closely watching for key support levels and potential market corrections.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards amidst Bitcoin's recent volatility, sparking debates about its correlation with BTC and potential risks. Community discussions range from concerns about margin calls and possible delisting to speculation on a potential bottom, with some traders eyeing a bounce while others foresee further declines. The stock's performance is closely tied to Bitcoin's price movements and Michael Saylor's strategy, leading to heightened uncertainty and a wide range of opinions.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending as investors discuss its correlation to Ethereum's price movements and upcoming earnings, with many expressing concerns over recent price drops and the impact of crypto market volatility. The community is actively debating the influence of figures like Tom Lee and Cathie Wood, while also pondering potential catalysts such as staking announcements and possible market manipulation. Discussions include BMNR's NAV, potential risks, and the overall sentiment surrounding crypto investments.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is trending following earnings, with community members pointing to strong revenue growth and a significant EPS beat. Despite positive results, some express concern about the overall market conditions and potential dilution, while others remain bullish, anticipating future upgrades and a rise in stock price. Discussions also revolve around institutional interest and comparisons to similar companies like Robinhood.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending amid volatility, with investors reacting to a UBS price target increase and broader market concerns. Community discussions revolve around whether the recent selloff presents a buying opportunity or signals an overbought condition, especially with Nvidia's earnings on the horizon. Sentiment is mixed as some anticipate a continued rally driven by AI memory demand, while others foresee a deeper correction.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

$BOB is trending as a novel token on the ICP blockchain, drawing comparisons to an early-stage Bitcoin due to its limited supply and halving schedule, sparking community interest. Discussions revolve around its potential for significant growth, particularly in relation to the ICP ecosystem, with some viewing it as a way to support the network. The community is closely watching upcoming halving events and their potential impact on price.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

LEU is trending due to a multi-billion dollar investment in its uranium enrichment expansion, sparking bullish sentiment. The community is discussing the potential for a short squeeze given the high short interest and small float. Broader context includes rising interest in nuclear energy, driven by AI and national security concerns.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk ($SNDK) is trending due to significant volatility and a recent price surge driven by optimism around the memory market and AI data center demand. The stock experienced a large pullback after hitting new highs, sparking debates about its valuation, potential overextension, and whether it's primed for a bounce or further decline. Community members are actively discussing swing trading opportunities versus long-term holds, and speculating about possible acquisitions.

ETF Opportunities Trust - T-REX 2X Long BMNR Daily Target ETF

T-REX 2X Long BMNR Daily Target ETF

The T-REX 2X Long BMNR Daily Target ETF ($BMNU) is trending as traders discuss its potential for gains amidst fluctuations in Ethereum ($ETH) and its underlying asset, Bit Mining ($BMNR). Community chatter revolves around the ETF's leveraged exposure, with some expressing concerns about potential reverse splits and others anticipating a significant rally if Ethereum rebounds. The conversation also highlights the debate around its tracking accuracy and suitability for short-term trading.

Copart, Inc. engages in the provision of online auctions and vehicle remarketing services. The firm offers vehicle sellers a full range of services to process and sell vehicles primarily over the internet through Virtual Bidding Third Generation Internet auction-style sales technology. It sells vehicles principally to licensed vehicle dismantlers, rebuilders, repair licensees, used vehicle dealers, exporters and at certain locations, and the public. The company’s services include online seller access, salvage estimation services, estimating services, end-of-life vehicle processing, virtual insured exchange, transportation services, vehicle inspection stations, on-demand reporting, DMV processing, and vehicle processing programs. It operates through the United States and International segments. The company was founded by Willis J. Johnson in 1982 and is headquartered in Dallas, TX.

Copart, Inc.

Copart's recent earnings are driving discussion, with the community analyzing whether the results justify the stock's valuation amid strong revenue and EPS figures. Community members are closely monitoring the company's performance, particularly its cash position and potential for strategic acquisitions or buybacks. The stock's potential to outperform in a correcting market, and its position within the broader vehicle auction and e-commerce landscape, also remain key talking points.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Southeast Asia’s Grab Holdings (GRAB) announced on Monday that it is investing $60 million in remote-driving technology provider Vay Technology in exchange for a minority equity stake in the startup.The investment is subject to regulatory approval and expected to close in the fourth quarter. &nbsp;<h2 class="st-heading-2">Investment Terms</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.grab.com/news-and-events/news-details/2025/Grab-to-make-a-strategic-investment-in-the-remote-driving-technology-company-Vay-2025-_cFcrFQjS-/default.aspx">added</a> that the funding could increase to a total of $410 million if Vay hits certain milestones within the first year of funding. The financial and operating milestones include consumer revenue, U.S. cities covered, technology and safety standards, and obtaining regulatory approvals for operating in additional U.S. cities.“We believe the future of mobility in Southeast Asia will be a hybrid model that relies on the expertise of our driver-partners alongside autonomous vehicles and remote driving services,” Grab CEO Anthony Tan said.Tan also expressed optimism that the initial investment would accelerate Vay’s remote driving technology development and expansion in the U.S. Grab will further explore how Vay’s service model can complement Grab’s suite of mobility services in Southeast Asia.The company noted that the investment supports its autonomous mobility strategy. Grab has previously also invested in other autonomous driving players, including WeRide and May Mobility.<h2 class="st-heading-2">Vay’s Modus Operandi</h2>Vay caters to a segment of consumers who prefer not to own a car by offering an on-demand car rental service enabled by remote driving technology. Customers can request an electric vehicle to be remotely delivered to their location through the Vay mobile app. Once the vehicle arrives, the user takes over, driving it like a regular car. At the end of the trip, they exit the vehicle, and a remote driver resumes control. A remote driver, hence, operates the vehicles only at the beginning and end of each rental, allowing the remote driver to support more customer trips every hour.Vay launched its remote-driven commercial fleet in Las Vegas in 2024. The company is now looking to expand its fleet.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GRAB">GRAB stock</a> stayed within the ‘bullish’ territory while message volume stayed at ‘extremely high’ levels over the past 24 hours.GRAB stock is up by 18% this year and by about 27% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ipha-stock-soars-pre-marker-after-fda-clears-late-stage-trial-for-lacutamab-in-rare-skin-cancers/cLPc04NRE2R">IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Grab logo displayed on a phone screen is seen in this illustration photo taken in Krakow, Poland on July 8, 2021. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Grab Deepens Autonomous Mobility Push With $60 Million Investment In Vay

The investment is subject to regulatory approval and expected to close in the fourth quarter. 

Equity

The investment is subject to regulatory approval and expected to close in the fourth quarter. 


<ul class="summary-bullets"><li>Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z.</li><li>The decision follows a report on October 24 of heightened liver transaminases and increased total bilirubin in a patient who was dosed with Nex-z in a trial.</li><li>The patient is being closely monitored and receiving medical intervention, the company said. &nbsp;</li></ul>Intellia Therapeutics, Inc. (NTLA) on Monday said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z after a patient was hospitalized.The company has paused dosing in a trial that enrolled patients with transthyretin amyloidosis with cardiomyopathy and another that enrolled patients with polyneuropathy. Transthyretin amyloidosis with cardiomyopathy is a severe and progressive heart failure caused by the buildup of misfolded amyloid fibrils, derived from the transthyretin protein, in the heart muscle. Transthyretin amyloidosis with polyneuropathy, meanwhile, is a progressive, multisystem disease caused by the buildup of abnormal proteins in the body's organs and tissues.&nbsp;<h2 class="st-heading-2">Why The Pause?</h2>The decision follows a report on October 24 of heightened liver transaminases and increased total bilirubin in a patient who was dosed with Nex-z in a trial, raising concerns of drug-induced liver injury. The patient was dosed with Nex-z on September 30.The hospitalized patient is being closely monitored and receiving medical intervention, the company said.<h2 class="st-heading-2">What Are The Company’s Plans?</h2>Meanwhile, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174462/0/en/Intellia-Therapeutics-Provides-Update-on-MAGNITUDE-Clinical-Trials-of-Nexiguran-Ziclumeran-nex-z.html">said</a> it is consulting with experts, considering potential risk mitigation strategies, and engaging with regulatory authorities.<blockquote>“In line with our commitment to patient safety, we have taken immediate action to temporarily pause enrollment in MAGNITUDE and MAGNITUDE-2 as we investigate this recent event. As we focus on ensuring the health of this patient, we also are engaging with regulatory authorities and other stakeholders globally to develop a strategy to resume enrollment as soon as appropriate.”&nbsp; – John Leonard, CEO, Intellia Therapeutics</blockquote>Nex-z or Nexiguran Ziclumeran is a therapy based on gene editing technology. It is designed to inactivate the TTR gene that encodes the transthyretin protein. As of Monday, more than 700 patients have been enrolled in the two trials in which Intellia has paused dosing, and over 450 have already been dosed with Nex-z.Shares of the company slumped 43% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> soared from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.NTLA stock has more than doubled this year and gained about 57% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bbio-stock-soars-after-experimental-drug-shows-improvement-in-inherited-muscle-disorder-in-late-stage-trial/cLG04ksR3Mm">BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

Why Did NTLA Stock Tumble 43% Pre-Market Today?

Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z.

Leerink lowered its price target on Rocket Pharmaceuticals (RCKT) to $7 from $9 on Friday, following the company's announcement that it has voluntarily withdrawn its application for the approval of Fanskya to the U.S. Food and Drug Administration for the treatment of Fanconi Anemia.The analyst kept a ‘Market Perform’ rating on the shares, according to TheFly. The new price target, however, implies a potential upside of approximately 118% from the stock’s closing price on Thursday.Rocket Pharma <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001281895/000114036125037163/ef20056613_8k.htm">stated</a> in a filing with the Securities and Exchange Commission that the decision to withdraw the application for the gene therapy follows its decision to focus its resources on programs with the clearest regulatory and commercial pathways. The decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya or RP-L102, the company said.“Data generated to date continue to support that RP-L102 has been generally well tolerated, with no significant safety signals observed, and a risk-benefit profile that appears favorable,” it added.The company ceased internal investment in Fanskya in July 2025 and withdrew its application with the European Medicines Agency (EMA) as part of a pipeline prioritization and corporate reorganization plan. The company had then warned that FDA approval of Fanskya is no longer expected in 2026.The therapy was tested in the treatment of Fanconi Anemia, a rare, inherited disorder characterized by a failure of the bone marrow to produce enough blood cells, leading to symptoms like fatigue, bleeding, and infections, as well as physical abnormalities and a significantly increased risk of certain cancers. &nbsp;The company said on Friday that it will consider external partnership opportunities to advance Fanskya in the future. “Withdrawal of the BLA preserves Rocket’s ability to re-engage with regulators at a later date should there be an appropriate strategic or partnership pathway to sustainably progress the program,” it said.<a href="https://stocktwits.com/symbol/RCKT">Shares of RCKT</a> fell 2% at the time of writing. On Stocktwits, retail sentiment around RCKT remained within the ‘bearish’ territory while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:578/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_57_15_PM_png_0ff4527f20.webp" alt="RCKT's Sentiment Meter and Message Volume as of 12:57 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="578" height="63"><figcaption>RCKT's Sentiment Meter and Message Volume as of 12:57 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure> In August, Rocket Pharma <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> that the FDA had lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.RCKT stock is down by 75% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-stock-soars-after-fda-grants-fast-track-designation-to-schizophrenia-drug/chCuoM8R3QK">Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sculpture depicting a DNA strand in front of the Lawrence Hall of Science at UC Berkeley on Saturday, March 31, 2018. (Photo By Paul Chinn/The San Francisco Chronicle via Getty Images)

Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy

The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya. 

Intellia Therapeutics (NTLA) shares received a price target revision from H.C. Wainwright on Friday, with analyst Mitchell Kapoor raising the target to $30 from $25, following the stock's 30% rally on Thursday.The analyst kept a ‘Buy’ rating on the shares. The new price target implies an 86% upside to the stock’s closing price on Thursday.Intellia <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-completes-enrollment-global-phase-3-haelo">said</a> on Thursday that it has completed enrollment in the global late-stage HAELO study of Lonvoguran Ziclumeran (lonvo-z) for the treatment of hereditary angioedema. Data from the trial is expected to be released in the first half of 2026.According to Kapoor, the company’s nine-month enrollment completion in the pivotal late-stage trial shows the pull for a one-time therapy, as reported by TheFly.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:578/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_8_00_44_AM_png_583e54e2a8.webp" alt="NTLA's Sentiment Meter and Message Volume as of 8:00 a.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="578" height="64"><figcaption>NTLA's Sentiment Meter and Message Volume as of 8:00 a.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded positive on the stock in the wake of the upcoming data from the study.<stembedurl>https://stocktwits.com/AdiKrononaut/message/629242354</stembedurl>Hereditary angioedema (HAE) is a rare, genetic disease characterized by severe, recurring, and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating, and life-threatening. It is estimated that one in 50,000 people is affected by HAE, Intellia said.The company said on Thursday that it is on track to apply for approval of Ionvo-z in the second half of 2026 and plans a U.S. launch for the therapy in the first half of 2027.Intellia dosed the first patient in the study in January 2025. The trial is designed to evaluate the efficacy and safety of lonvo-z in at least 60 adults and adolescents aged 16 years and older with Type I or Type II HAE. Key endpoints for the study include the number of HAE attacks and the number of patients who achieve attack-free status from week five through week 28.INTL stock is up &nbsp;by 38% this year, but down by about 30% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/merck-says-ema-committee-adopted-two-positive-opinions-for-expanding-use-of-keytruda/chD3GzKR3Rp">Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details

The new price target of $30 implies an 86% upside to the stock’s closing price on Thursday. 

Summit Therapeutics (SMMT) shares were in the spotlight on Thursday after Guggenheim initiated coverage of the stock with a ‘Buy’ rating and a $40 price target.The price target represents a 70% upside from the stock’s closing price on Wednesday. SMMT stock has had a good run over the past year, nearly doubling in value.Guggenheim said that it liked Summit at $3 when the market was overlooking imminent data comparing progression-free survival with Summit’s Ivonescimab versus Merck's (MRK) blockbuster drug Pembrolizumab in lung cancer. Notably, the analyst said that they still like the stock at $24.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SMMT">SMMT stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, &nbsp;while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:585/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_11_41_23_AM_png_000895180e.webp" alt="SMMT's Sentiment Meter and Message Volume as of 11:41 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="585" height="62"><figcaption>SMMT's Sentiment Meter and Message Volume as of 11:41 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they see sustained growth potential for the stock.<stembedurl>https://stocktwits.com/db59/message/627464707</stembedurl>Guggenheim stated that if Summit's two late-stage clinical trials, HARMONi-3 and HARMONi-7, evaluating Ivonescimab in non-small cell lung cancer (NSCLC) are successful on progression-free survival or overall survival endpoints in 2027-2028, it has high conviction that the stock still has multi-fold upside potential from today's near-$20 billion valuation.While progression-free survival (PFS) is the length of time a patient with a disease, such as cancer, lives with the disease without it getting worse, or dies, overall survival (OS) is the total length of time a patient lives from the point of diagnosis or the start of treatment until death.HARMONi-3 is intended to evaluate Ivonescimab combined with chemotherapy compared to Pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous and non-squamous NSCLC. HARMONi-7 is intended to evaluate Ivonescimab monotherapy compared to Pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors produce a high amount of the PD-L1 protein.SMMT stock is up 32% this year and approximately 96% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/agios-pharma-stock-slumps-but-company-remains-top-pick-for-analyst/chwdJJlRdYs">Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3

The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday.

ESGV
Vanguard Group, Inc. - Vanguard ESG U.S. Stock ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ESGV News

ESGVVanguard Group, Inc. - Vanguard ESG U.S. Stock ETF